Quantification of olaparib in human liver microsomes using an ultra-fast UPLC-MS/MS quantitative approach: in vitro and in silico metabolic stability assessment
Abstract
studies suggest that minor structural modifications of the phthalazin-1-one (52%) and piperazine (24%) moieties during drug design may improve the safety profile and metabolic stability of new derivatives compared with OLA; however, experimental confirmation is needed.
Fields of Study & Subjects
PARP inhibition in cancer therapy
Advanced Breast Cancer Therapies
Sirtuins and Resveratrol in Medicine
Publication details
- Journal / source
- The Analyst
- Publisher
- Royal Society of Chemistry (RSC)
- Volume
- 151
- Issue
- 7
- Pages
- 2098–2108
- Publication date
- 1 January 2026
- Language
- EN